<DOC>
	<DOCNO>NCT00003273</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness different regimen combination chemotherapy follow peripheral stem cell transplantation treat child newly diagnose brain tumor .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Children With Newly Diagnosed Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Investigate toxicity response rate intensification induction chemotherapy regimen ( regimen A : cisplatin , vincristine , cyclophosphamide , etoposide ) incorporation high-dose methotrexate leucovorin calcium rescue patient primitive neuroectodermal tumor evidence leptomeningeal dissemination ( M1 , M2 , M3 ) . - Investigate toxicity response rate new dose intensive induction chemotherapy regimen ( regimen C : vincristine , carboplatin , temozolomide ) child ten year age newly diagnose either high grade glioma diffuse intrinsic pontine tumor . ( Regimen B close accrual effective 3/30/2000 ; regimen C open accrual effective 7/21/2000 ) - Investigate feasibility utilize regimen C chemotherapy follow consolidation myeloablative chemotherapy autologous stem cell ( either bone marrow and/or peripheral blood ) rescue patient . ( Regimen B close accrual effective 3/30/2000 ; regimen C open accrual effective 7/21/2000 ) - Investigate toxicity response rate intensification induction regimen A chemotherapy incorporation high-dose methotrexate leucovorin calcium rescue patient primitive neuroectodermal tumor evidence leptomeningeal dissemination ( M1 , M2 , M3 ) . - Estimate time disease progression pattern relapse patient radiographic cytologic evidence residual disease time consolidation chemotherapy , therefore , receive post consolidation irradiation . - Estimate time disease progression pattern relapse patient radiographic cytologic evidence residual disease time consolidation chemotherapy , therefore , receive post consolidation irradiation . - Assess morbidity mortality consolidation chemotherapy regimen follow either regimen C intensify regimen A patient . ( Regimen B close accrual effective 3/30/2000 ; regimen C open accrual effective 7/21/2000 ) - Assess impact irradiation avoidance administration reduce volume craniospinal and/or focus field local irradiation neuropsychometric , endocrinological function , physical growth . OUTLINE : This two regimen study base disease characteristic . Patients regimens A , B , C undergo leukapheresis receiving filgrastim ( G-CSF ) subcutaneous ( SC ) injection . - Regimen A : Patients without evidence neuraxis dissemination receive five 21 day course follow chemotherapy : cisplatin IV 6 hour day 0 ; etoposide cyclophosphamide IV 1 hour day 1 2 ; vincristine IV day 0 , 7 , 14 course 1 , 2 , 3 ; G-CSF SC begin day 3 course continue blood count recover 48 hour start next course . Patients evidence neuraxis dissemination also receive high-dose methotrexate IV 4 hour day 3 leucovorin calcium orally IV bolus start 24 hour prior methotrexate continue every 6 hour methotrexate level diminish . - Regimen B ( close accrual effective 3/30/2000 ) : Patients receive three 21-28 day course follow chemotherapy : vincristine IV day 0 , 7 , 14 course ; carboplatin IV 4 hour day 3 4 course ; oral procarbazine daily day 0-4 ; oral lomustine day 3 4 ; G-CSF SC daily begin 24 hour follow last dose carboplatin continue blood count recover 48 hour start next course . On day 7 course , patient also receive peripheral blood stem cell ( PBSC ) reinfusion follow chemotherapy . Oral lomustine administer first two course . - Regimen C ( open accrual effective 07/21/2000 ) : Patients receive four 28 day course follow chemotherapy : carboplatin IV 4 hour day 0 1 course ; vincristine IV day 0 , 7 , 14 first three course ; oral temozolomide daily day 0-4 ; G-CSF SC daily begin day 5 continue blood count recover . After regimen A , B , C absence disease progression , patient undergo consolidation myeloablative chemotherapy receive carboplatin IV 4 hour day -8 , -7 , -6 , thiotepa IV 3 hour follow etoposide IV day -5 , -4 , -3 . Patients malignant glioma unbiopsied diffuse intrinsic pontine tumor receive etoposide . On day 0 , patient reinfused autologous PBSC . Following recovery consolidation chemotherapy , patient radiographic cytologic evidence residual disease undergo radiotherapy . Patients follow 3 month , every 3 month first 2 year , every 6 month year 2-4 , annually thereafter . PROJECTED ACCRUAL : Approximately 96 patient ( 73 regimen A 23 regimen C ) accrue study . ( Regimen B close accrual effective 3/30/2000 . )</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant , newly diagnose brain tumor Regimen A : Posterior fossa medulloblastoma/primitive neuroectodermal tumor ( PNET ) : All stage , 3 year diagnosis OR High stage ( local residual tumor postoperatively and/or neuraxis extraneural dissemination ) , 310 year diagnosis Supratentorial PNET , pineoblastoma , cerebral neuroblastoma , ependymoblastoma , medulloepithelioma , medullomyoblastoma : All stage , 10 year diagnosis Brainstem PNET : All stage , irrespective extent resection , 10 year diagnosis Ependymoma anaplastic ependymoma : All stage , location ( except primary spinal cord ependymoma ) , 3 year diagnosis OR Local residual tumor postoperatively and/or neuraxis dissemination , location , 310 year diagnosis Supratentorial ependymoma : All stage , irrespective extent resection , 10 year diagnosis , exclude gross totally resect ( confirm postoperative MRI ) low grade ependymoma invade ventricular system Metastatic retinoblastoma : Previously untreated ( except cryosurgery laser surgery ) , 10 year presentation metastatic disease Primary atypical teratoid/rhabdoid tumor CNS : Under 10 year diagnosis Choroid plexus carcinoma : Incompletely resect , site , 10 year diagnosis Regimen C : Anaplastic astrocytoma , glioblastoma multiforme , anaplastic oligodendroglioma , anaplastic ganglioglioma , anaplastic mixed glioma : Under 10 year diagnosis Diffuse intrinsic pontine tumor : Unbiopsied , 10 year diagnosis The following diagnosis eligible : Myxopapillary ependymoma spinal cord , low grade brainstem astrocytoma , primary CNS lymphoma solid leukemic lesion ( i.e. , chloroma , granulocytic sarcoma ) , primary CNS germ cell tumor PATIENT CHARACTERISTICS : Age : Under 10 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 mg/dL SGPT le 2.5 time upper limit normal Renal : Creatinine clearance great 60 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow No concurrent corticosteroid sole purpose antiemesis Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
</DOC>